 |
 |

Treating Alzheimer Disease
Time Matters
Arch Neurol. 2006;63:926-928.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Alzheimer disease is a progressive and unrelenting neurodegenerative disorder causing incremental cognitive decline due to increasing neuropathologic changes including amyloid-containing neuritic plaques, aggregated hyperphosphorylated tau as neurofibrillary tangles, dystrophic neurites, gliosis, and synaptic and neuronal loss. These changes have been established findings for many years, and the impression is that they are permanent and fixed. What has emerged in recent years using transgenic mouse models containing mutant genes causal of Alzheimer disease is that these neuropathologic fixtures can indeed be altered and changed, and they have even been shown to regress.
The 2006 Potamkin Prize for Research in Picks, Alzheimer, and Related Disorders was given by the American Academy of Neurology, St Paul, Minn, to Bradley Hyman, MD, PhD, Karen H. Ashe, MD, PhD, and Karen E. K. Duff, PhD, for their complementary and collective research in developing transgenic mouse models containing mutant amyloid precursor protein, presenilin, and tau genes . . . [Full Text of this Article] AUTHOR INFORMATION
Roger N. Rosenberg, MD, Editor
RELATED ARTICLE
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid -Amyloid 42 in Adults With Normal Cognition
Elaine R. Peskind, Ge Li, Jane Shofer, Joseph F. Quinn, Jeffrey A. Kaye, Chris M. Clark, Martin R. Farlow, Charles DeCarli, Murray A. Raskind, Gerard D. Schellenberg, Virginia M.-Y. Lee, and Douglas R. Galasko
Arch Neurol. 2006;63(7):936-939.
ABSTRACT
| FULL TEXT
|